Clinical Trial Update: Extension to a Study to Assess the Efficacy and Safety of Three Doses of Vildagliptin in Patients With Type 2 Diabetes [Phase 3]

View source ↗

Summary

This document provides an extension study update evaluating three doses of vildagliptin in patients with Type 2 diabetes mellitus, focusing on efficacy and safe…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Galvus (vildagliptin)

Snippet

Sponsor: Novartis | Conditions: Diabetes Mellitus, Type 2 | Phase 3 | Status: COMPLETED